[1] DANIELS G L,SIMARD H,GOLDMAN M,et al.PEL,a 'new' high-frequency red cell surface antigen[J].Vox Sang,1996,70(1):31-33.
[2] AZOUZI S,MIKDAR M,HERMAND P,et al.Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation[J].Blood,2020,135(6):441-448.
[3] ANDERSON G,DONNELLY S,BRADY T,et al.An antibody to a high-frequency antigen found on red-cells,platelets,lymphocytes,and monocytes[J].Transfusion,1993,33(9): S23.
[4] THORNTON N,KARAMATIC CREW V,TILLEY L,et al.Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotype[J].Nat Commun,2020,11(1): 3569.
[5] DANIELS G L,TALIANO V,KLEIN M T,et al.Emm.A red cell antigen of very high frequency[J].Transfusion,1987,27(4):319-321.
[6] WAGNER M M,VAN DUNNÉ F M,KUIPERS I,et al.Anti-Emm in a pregnant patient——case report[J].Vox Sang,2014,106(4):385-386.
[7] LOMAS-FRANCIS C.Clinical significance of antibodies to antigens in the International Society of Blood Transfusion collections,700 series of low-incidence antigens,and 901 series of high-incidence antigens[J].Immunohematology,2018,34(2):39-45.
[8] FLEGEL W A,SRIVASTAVA K,SISSUNG T M,et al.Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes[J].Vox Sang,2021,116(2):141-154.
[9] FÜRST D,TSAMADOU C,NEUCHEL C,et al.Next-generation sequencing technologies in blood group typing[J].Transfus Med Hemother,2020,47(1):4-13.
[10] GLEADALL N S,VELDHUISEN B,GOLLUB J,et al.Development and validation of a universal blood donor genotyping platform: a multinational prospective study[J].Blood Adv,2020,4(15):3495-3506.
[11] VORHOLT S M,HAMKER N,SPARKA H,et al.High-throughput screening of blood donors for twelve human platelet antigen systems using next-generation sequencing reveals detection of rare polymorphisms and two novel protein-changing variants[J].Transfus Med Hemotherapy,2020,47(1):33-44.
[12] LO Y M,CORBETTA N,CHAMBERLAIN P F,et al.Presence of fetal DNA in maternal plasma and serum[J].Lancet,1997,350(9076):485-487.
[13] HYLAND C A,O'BRIEN H,FLOWER R L,et al.Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation[J].Transfus Apher Sci,2020,59(5):102947.
[14] ERYILMAZ M,MÜLLER D,RINK G,et al.Introduction of noninvasive prenatal testing for blood group and platelet antigens from cell-free plasma DNA using digital PCR[J].Transfus Med Hemother,2020,47(4): 292-301.
[15] RYCZEK E,WHITE J,CAROLAN-REES G.Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews[J].Transfus Med,2020,30(4):287-294.
[16] MENEGATI S F P,SANTOS T D,MACEDO M D,et al.Discrepancies between red cell phenotyping and genotyping in daily immunohematology laboratory practice[J].Transfus Apher Sci,2020,59(1):102585.
[17] MARSH J C,STANWORTH S J,PANKHURST L A,et al.An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial[J].Blood,2021,137(3):310-322.
[18] KALLON D,NAVARRETE C V,SAGE D A,et al.Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients[J].Transfus Med,2020,30(1):23-29.
[19] LALLY K,KRUSE R L,SMETANA H,et al.Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing[J].Transfusion,2020,60(3):628-636.
[20] ADKINS B D,ARNOLD EGLOFF S A,FAHEY-AHRNDT K,et al.An exploration of the advantages of automated titration testing: low inter-instrument variability and equivalent accuracy for ABO and non-ABO antibody titres relative to tube testing[J].Vox Sang,2020,115(4):314-322.
[21] YANG J J,SEO S W,KIM J S,et al.A comparison of the automated blood bank system IH-500 and manual tube method for anti-blood group antibody titration: a quantitative approach[J].Transfus Apher Sci,2020,59(4):102806.
[22] BUCHTA C,COUCKE W,MAYR W R,et al.To win the battle,first know your enemy: error rates in immunohematology external quality assessment results[J].Transfus Med Hemother,2020,47(1): 80-87.
[23] YE Z,WOLF L A,METTMAN D,et al.Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab[J].Vox Sang,2020,115(2): 207-212.
[24] IZAGUIRRE E C,DEL MAR LUIS-HIDALGO M,GONZÁLEZ L L,et al.New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing[J].Trasfusione Del Sangue,2020,18(4):290-294.
[25] FURUMAKI H,TAKESHITA A,OHTO H,et al.A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells[J/OL].Vox Sang,2020(2020-12-13). https://onlinelibrary.wiley.com/doi/10.1111/vox.13052
[26] TREMBLAY T,BRANCH D R,LOUBAKI L.Daudi cell stroma: an alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing[J].Transfusion,2020,60(9):2090-2096.
[27] KIM T Y,YOON M S,HUSTINX H,et al.Assessing and mitigating the interference of ALX148,a novel CD47 blocking agent,in pretransfusion compatibility testing[J].Transfusion,2020,60(10):2399-2407.
[28] ANSTEE D J.The relationship between blood groups and disease[J].Blood,2010,115(23):4635-4643.
[29] LI J,WANG X,CHEN J,et al.Association between ABO blood groups and risk of SARS-CoV-2 pneumonia[J].Br J Haematol,2020,190(1):24-27.
[30] FRANCHINI M,GLINGANI C,DEL FANTE C,et al.The protective effect of O blood type against SARS-CoV-2 infection[J].Vox Sang,2021,116(2):249-250. |
